Trial Profile
A Randomized, Open-label, Two-way, Crossover Study to Evaluate the Relative Bioavailability of Apalutamide Administered Orally as Whole Tablets and as a Mixture in Applesauce in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Mar 2022
Price :
$35
*
At a glance
- Drugs Apalutamide (Primary)
- Indications Prostate cancer
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 30 Apr 2019 Status changed from recruiting to completed.
- 28 Feb 2019 Planned End Date changed from 28 Mar 2019 to 11 Apr 2019.
- 21 Jan 2019 New trial record